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Objectives The ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–
Thrombolysis In Myocardial Infarction 25) trial provided the opportunity to evaluate the impact of renal dysfunc-
tion on outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and compare enoxaparin
(ENOX) and unfractionated heparin (UFH).
Background It is unclear how renal dysfunction influences the balance between benefit and risk of antithrombotic therapy.
Methods In the ExTRACT-TIMI 25 trial, 20,479 patients were randomized to UFH or ENOX. A reduced ENOX dose was ad-
ministered to patients age 75 years and those with an estimated creatinine clearance (CrCl) 30 ml/min.
Results A powerful relationship was observed between the severity of renal dysfunction (per 10 ml/min decrement in
CrCl) and death, stroke, intracranial hemorrhage, and major and minor bleeding (p  0.001 for each). There was
a progressive increase in the treatment benefit with ENOX on death or nonfatal myocardial infarction (p  0.01)
with better renal function. Net clinical benefit (death, nonfatal MI, or nonfatal major bleeding) was significantly
superior with ENOX (p  0.001) for patients with a CrCl 60 ml/min (79.1% of the study population). Major
bleeding and intracranial hemorrhage did not differ for patients with preserved renal function (CrCl 90 ml/
min), but in those with renal dysfunction there was a progressively greater increase in the risk of major and mi-
nor bleeding with ENOX.
Conclusions Enoxaparin was superior to UFH for the majority of subjects. With more severe renal dysfunction, the net clinical
benefit between ENOX and UFH did not differ, despite the rise in adverse events in both treatment groups. Fu-
ture studies should take renal dysfunction into account when assessing antithrombotic regimens. (J Am Coll
Cardiol 2007;49:2249–55) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.049d
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watients with acute coronary syndromes and renal dysfunc-
ion have been observed to have increased risks of adverse
vents in epidemiological studies (1–5), observational stud-
es, and clinical trials (6–13). These events include death,
troke, and bleeding. However, it is unclear whether renal
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006, accepted December 10, 2006.ysfunction influences the balance between benefit and risk
n the context of antithrombotic therapy in patients with
T-segment elevation myocardial infarction (STEMI) un-
ergoing fibrinolysis. The issue is important, because world-
ide the majority of patients with STEMI undergoing
eperfusion continue to receive fibrinolytic therapy.
The ExTRACT-TIMI 25 (Enoxaparin and Thrombol-
sis Reperfusion for Acute Myocardial Infarction Treatment–
hrombolysis In Myocardial Infarction 25) trial compared a
trategy of enoxaparin (ENOX) with a strategy of unfrac-
ionated heparin (UFH) as an adjunct to fibrinolytic therapy
or STEMI (14). The ENOX strategy was significantly
uperior to the UFH strategy in reducing death or nonfatal
einfarction through 30 days. Major bleeding was increased
ith ENOX, but net clinical benefit favored ENOX (14).
he ExTRACT-TIMI 25 trial provides the opportunity to
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grees of renal dysfunction on
outcomes in STEMI patients
and to test whether the balance
of risk versus benefit of ENOX
compared with UFH was influ-
enced by the extent of renal
dysfunction.
Methods
The design, patient population,
and study protocol have been re-
ported in detail (15). In brief,
20,479 patients with STEMI
formed the intention-to-treat
cohort and were randomized
ithin 6 h of onset of symptoms. They had ST-segment
levation or left bundle-branch block and were scheduled to
ndergo fibrinolysis. Patients were excluded if they had
ardiogenic shock, contraindications to fibrinolysis, or
nown renal insufficiency with serum creatinine 200
mol/l (2.5 mg/dl) for men and 175 mol/l (2.0 mg/dl)
or women (13). In addition to the fibrinolytic regimen all
atients received 150 to 325 mg of aspirin and maintenance
herapy of 75 to 325 mg of aspirin once daily. The evidence
n favor of clopidogrel treatment for STEMI emerged while
he ExTRACT-TIMI 25 trial was underway (16,17), and
linicians were allowed to administer clopidogrel at their
iscretion.
The study medication was administered in a double-blind
ashion with a double-dummy design. In patients age 75
ears, ENOX was administered as an initial 30-mg intra-
enous bolus followed by subcutaneous injections of
.0 mg/kg every 12 h (15). For patients age 75 years, the
ntravenous bolus was omitted and the maintenance dose
as reduced to 0.75 mg/kg every 12 h. For patients of any
ge with an estimated creatinine clearance (CrCl) 30
l/min, the dose was reduced to 1 mg/kg every 24 h. The
osing strategy described in the preceding text was designed
o as not to interfere with the goal of prompt administration
f pharmacologic reperfusion (lytic and initial dosing of
djunctive therapy), because the adjustment of ENOX
osing for CrCl 30 ml/min does not need to occur until
2 h after the initial dose, by which time the serum
reatinine has returned from the chemistry laboratory and
rCl can be estimated. The double-blind subcutaneous
njections of ENOX or matching placebo were continued
ntil hospital discharge or a maximum of 8 days. The UFH
as administered as an intravenous bolus of 60 U/kg
maximum 4,000 U); this bolus was omitted in patients who
ad received open-label UFH within the 3 h prior to
andomization. The UFH was administered according to
he guideline recommended strategy for at least 48 h but
Abbreviations
and Acronyms
CI  confidence interval
CrCl  creatinine clearance
ENOX  enoxaparin
LMWH  low-molecular-
weight heparin
MI  myocardial infarction
ORadj  adjusted odds ratio
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
heparinould be continued longer at the treating physician’s discre- pion (18,19). The monitoring of UFH was performed in a
linded fashion.
The CrCl was estimated with the Cockcroft-Gault for-
ula (20,21), and the population was divided according to
trata of CrCl (30 ml/min, 30 to 60 ml/min, 60 to 90
l/min, and 90 ml/min).
The primary end point of the trial was the composite of
eath from any cause or nonfatal recurrent myocardial
nfarction (MI) within the first 30 days of randomization
12,13). Bleeding was classified according to the TIMI
riteria (15). All ischemic and clinically significant bleed-
ng events were adjudicated in a blinded fashion by an
ndependent clinical-events committee with prespecified
efinitions (15).
tatistical analyses. All efficacy analyses were based on the
ntention-to-treat principle. Safety analyses were performed
ccording to the treatment actually received. Continuous
ariables are presented as median and interquartile range,
nd categorical variables are presented as frequencies. In the
omparison of baseline characteristics stratified by CrCl
trata (see preceding text), differences in continuous vari-
bles were analyzed with the Kruskal-Wallis rank test, and
ifferences in categorical variables were analyzed with the
hi-square test. Frequency of efficacy and safety outcomes at
0 days were compared with the categorical CrCl variable
nd analyzed with the chi-square test as well as the test for
rend.
Logistic regression models for efficacy and safety out-
omes were performed with a 10 ml/min decrease in CrCl,
djusting for components of the TIMI risk score (22) with
he exception of age (which is included in the estimation of
he CrCl by the Cockroft-Gault formula), and the results
re presented as adjusted odds ratio (ORadj). The elements of
he TIMI risk score for STEMI include: systolic blood
ressure 100 mm Hg (3 points); heart rate 100 beats/min
2 points); Killip class II to IV (2 points); anterior ST-
egment elevation or left bundle branch block (1 point);
iabetes, history of hypertension, or history of angina (1
oint); weight 67 kg (1 point); and time to treatment 4
(1 point). The treatment effect of the randomization
trategies (ENOX vs. UFH) was evaluated for efficacy and
afety outcomes, stratified by CrCl group (see Table 1 for
efinitions of CrCl groups) with a chi-square test. All
tatistical analyses were performed with Stata/SE version
.1 (Stata Corp., College Station, Texas).
esults
ssessment of baseline characteristics showed that for each
f the major risk characteristics there was an inverse
elationship between the stratum of CrCl and the severity of
he risk characteristics (Table 1). For example, patients in
ach lower stratum of CrCl were older and more frequently
ad hypertension, diabetes, previous MI, and a higher
IMI risk score. Thus, the median age was 52 years in
atients with CrCl 90 ml/min and 78 years in those with
C
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TIMI risk score 3) in these 2 groups was 85.3% and
.5%, respectively. In addition, concomitant medications
ere used less frequently in patients with lower CrCl
Table 1).
Baseline Characteristics of Patients Stratified b
Table 1 Baseline Characteristics of Patients
Characteristic
<30
(n  212) (n
Age (yrs)
Median 78
Interquartile range 73–84
Male (%) 41.0
Weight, kg (median) 60
Hypertension (%) 65.6
Hyperlipidemia (%) 20.3
Current smoker (%) 12.3
Diabetes mellitus (%) 27.9
Prior MI (%) 24.0
Prior angina pectoris (%) 36.7
Anterior MI (%) 42.7
Killip class II (%) 25.5
TIMI risk score 3 (%)* 91.5
Fibrin-specific lytic (%)† 71.7
Lytic type (%)
Fibrin-specific† 71.7
Streptokinase 28.3
Cardiac medications during index
hospital stay (%)
Aspirin 82.1
Clopidogrel 17.5
Beta-blockers 64.6
ACE inhibitors or ARBs 64.6
Statins 58.5
*Excluding age, because it is included in estimation of creatinine cl
reteplase.
ACE  angiotensin-converting enzyme; ARB  angiotensin recepto
Thrombolysis In Myocardial Infarction.
Outcomes at 30 Days by CrCl (Full Trial Populat
Table 2 Outcomes at 30 Days by CrCl (Full
Outcome (%)
<30
(n  212) (n
Death or nonfatal re-MI 35.4
Death 31.1
Nonfatal re-MI 4.3
Urgent revascularization 0.5
Stroke 2.8
Death, nonfatal re-MI, or urgent
revascularization
35.4
Major bleeding (including ICH) 4.2
ICH 1.4
Minor bleeding 5.6
Death, nonfatal re-MI, or nonfatal
major bleeding*
36.3Values shown in CrCl strata represent percentages. *Net clinical benefit.
ICH  intracranial hemorrhage; other abbreviations as in Table 1.ffect of CrCl on outcomes (full trial population). For all
atients, a powerful and direct relationship was noted
etween the severity of renal dysfunction and death, stroke,
ajor bleeding, intracranial hemorrhage, and minor bleed-
ng (Table 2). A continuous inverse relationship was evident
l
tified by CrCl
CrCl (ml/min)
p Value
0
71)
>60–90
(n  7,203)
>90
(n  7,462)
0.001
63 52
7 55–69 46–58
76.1 88.2 0.001
74 84 0.001
44.5 37.9 0.001
18.2 17.8 0.82
44.1 61.5 0.001
14.7 12.8 0.001
13.7 10.6 0.001
29.0 23.9 0.001
44.1 43.6 0.04
11.5 8.1 0.001
37.7 11.8 0.001
80.7 82.3 0.001
0.001
80.7 82.3
19.3 18.5
95.2 97.5 0.001
28.5 28.6 0.001
85.4 90.0 0.001
80.3 80.6 0.001
68.4 72.4 0.001
. †Fibrinolytic group (fibrin specific)  tenecteplase or alteplase or
er; CrCl  creatinine clearance; MI  myocardial infarction; TIMI 
Population)
CrCl (ml/min)
p Value
for Trend
0
71)
>60–90
(n  7,203)
>90
(n  7,462)
10.9 6.2 0.001
7.1 2.6 0.001
3.8 3.5 0.14
2.3 2.4 0.77
1.5 0.5 0.001
13.0 8.3 0.001
1.9 1.0 0.001
1.1 0.2 0.001
2.0 1.4 0.001
11.9 6.8 0.001y CrC
Stra
30–6
 3,6
72
66–7
54.8
68
56.6
18.0
26.0
19.0
16.8
36.5
45.4
17.2
72.8
78.1
78.1
21.9
91.5
23.7
80.0
77.2
61.6
earanceion)
Trial
30–6
 3,6
19.4
15.3
4.1
2.7
2.5
21.6
2.7
1.2
4.3
20.9
b
p
b
n
(
C
p
S
o
(
p
r
9
M
d
f
r
(
(
9
1
i
(
C
o
E
f
d
t
(
m
s

g
a
t
r
r
2252 Fox et al. JACC Vol. 49, No. 23, 2007
Renal Dysfunction and the ExTRACT-TIMI 25 Trial June 12, 2007:2249–55etween CrCl and mortality (Fig. 1A), the primary end
oint (death or nonfatal recurrent MI) (Fig. 1B), major
leeding (Fig. 1C), and net clinical benefit (death or
onfatal recurrent MI or nonfatal major bleeding)
Fig. 1D).
In a univariate regression model, a 10-ml/min decrease in
rCl conferred an increased risk of death (OR 1.34,
 0.001) and of stroke at 30 days (OR 1.22, p  0.001).
imilarly, a 10-ml/min decrease in CrCl increased the risk
f both major (OR 1.15, p  0.001) and minor bleeding
OR 1.19, p  0.001).
In a multivariable regression model, adjusting for com-
onents of the TIMI risk score (excluding age), CrCl
emained an independent predictor of death (ORadj 1.27,
5% confidence interval [CI] 1.24 to 1.31, p  0.001).
ultivariate analysis confirmed the effect of a 10-ml/min
ecrement in CrCl in predicting an increased risk of the
ollowing additional events at 30 days: death or nonfatal
ecurrent MI (ORadj 1.14, 95% CI 1.13 to 1.17), stroke
ORadj 1.26, 95% CI 1.19 to 1.35), intracranial hemorrhage
Figure 1 Relationship Between Creatinine Clearance and Outco
Panels A to D plot the outcomes shown as estimated from a univariate regression
model treating creatinine clearance (CrCl) as a continuous variable. MI  myocardORadj 1.24, 95% CI 1.15 to 1.35), major bleed (ORadj 1.16, c5% CI 1.10 to 1.22), minor bleed (ORadj 1.16, 95% CI
.11 to 1.21) (p value for each 0.001). However, changes
n CrCl were not predictive of nonfatal recurrent MI alone
ORadj 1.01, 95% CI 0.99 to 1.04).
omparison between ENOX and UFH at varying levels
f renal function. The rates of death were similar for
NOX and UFH, irrespective of CrCl (Table 3). However,
or the composite of death or nonfatal recurrent MI at 30
ays (the primary end point of the ExTRACT-TIMI 25
rial), there were significant differences in favor of ENOX
pinteraction  0.005) (Table 3) that persisted after adjust-
ent for baseline risk (Table 4, Fig. 2). Major bleeding was
imilar in the 2 treatment groups for patients with CrCl
90 ml/min, but with increasing renal dysfunction a pro-
ressive excess in bleeding was seen with ENOX (Tables 3
nd 4). The rates of intracranial hemorrhage in the 2
reatment groups were low and did not differ across the
ange of renal dysfunction.
The primary end point, composite of death or nonfatal
ecurrent MI, and the net clinical benefit end point, a
rction.mes
ial infaomposite of the primary end point plus nonfatal major
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June 12, 2007:2249–55 Renal Dysfunction and the ExTRACT-TIMI 25 Trialleeding, favored ENOX and achieved statistical signifi-
ance in patients with preserved or only minor impairment
f renal function (CrCl 60 ml/min) (Table 3). This
onstituted the majority (79.1%) of the study population.
iscussion
n this large, multinational, and well characterized clinical
rial population, estimated CrCl varied substantially and
mpairment of renal function was a powerful determinant of
dverse outcome. These observations are consistent with
ata from both epidemiological (1–5) and observational
tudies (6–10) as well as clinical trials in various population
roups (11–13,23,24). Our findings illustrate the value of a
arge heterogeneous clinical trial population (as in the
xTRACT-TIMI 25 trial) to reflect clinical practice.
Renal dysfunction does not exist in isolation. The severity
f renal dysfunction was strongly associated with a series of
isk characteristics, evident at the time of presentation with
TEMI. These include older age, male gender, hyperten-
ion, diabetes mellitus, previous MI, previous angina pec-
oris, heart failure, and a higher TIMI risk score (22).
evertheless, previous studies have demonstrated the inde-
endence of renal dysfunction as a predictor of in-hospital
utcomes at 30 Days by Treatment Assignment
Table 3 Outcomes at 30 Days by Treatment Assignment
<30 30–6
ENOX
(n  106)
UFH
(n  106)
ENOX
(n  1,813)
Death or nonfatal re-MI* 33.0 37.7 19.4
Death 29.3 33.0 15.7
Nonfatal re-MI 3.8 4.7 3.8
Stroke 2.8 2.8 2.2
Major bleed (including ICH) 5.7 2.8 3.5†
ICH 1.9 0.9 1.2
Minor bleed 7.6 3.7 5.0§
Death/nonfatal re-MI,
nonfatal major bleed*
34.9 37.7 21.3
alues shown in CrCl strata represent percentages. *p  0.05 for interaction between randomiz
omparison of ENOX versus UFH. §p  0.05 for comparison of ENOX versus UFH. Net clinical ben
Abbreviations as in Tables 1 and 2.
utcomes at 30 Days by Randomized Treatment (Odds Ratio [95%
Table 4 Outcomes at 30 Days by Randomized Treatment (Odds
<30
Death or nonfatal re-MI 0.74 (0.38–1.44)
Death 0.75 (0.37–1.50)
Nonfatal re-MI 0.93 (0.22–3.83)
Stroke 0.94 (0.12–7.35)
Major bleed (including ICH) 3.60 (0.67–19.21)
ICH —
Minor bleed 1.68 (0.44–6.33)
Death/nonfatal re-MI nonfatal major bleed* 0.83 (0.43–1.60)djusted for components of TIMI risk score, with the exception of age (age included in the Cockcroft-Gau
CI  confidence interval; other abbreviations as in Tables 1 and 2.nd subsequent death (6,25). These findings are consistent
ith those seen from a broader range of patients with acute
oronary syndromes. In the ExTRACT-TIMI 25 trial,
rCl remained an independent predictor of death, stroke,
ntracranial hemorrhage, and both major and minor bleed-
ng, after adjustment for the components of the TIMI risk
core (p  0.001 for each comparison). Interestingly, no
ignificant association was demonstrated with nonfatal re-
urrent MI.
Major bleeding and intracranial hemorrhage were sys-
ematically and prospectively captured, and the rates of
hese bleeding complications of fibrinolytic therapy were
ower than those reported in recent similarly designed trials
26). Nevertheless, the longer-term adverse outcomes asso-
iated with bleeding have been increasingly recognized, and
ull assessment of adjunctive antithrombotic therapy re-
uires evaluation of benefits against bleeding risks. With
ach successive 30-ml/min stratum of declining CrCl, the
isk of major or minor bleeding increased by approximately
0% (ranging from 2.3% in patients with a CrCl 90
l/min to 9.4% in those with a CrCl 30 ml/min). Even
odest degrees of renal dysfunction (CrCl 60 ml/min)
ere associated with increased risks of major, minor, and
CrCl (ml/min)
>60–90 >90
FH
1,858)
ENOX
(n  3,583)
UFH
(n  3,620)
ENOX
(n  3,739)
UFH
(n  3,723)
9.4 9.6† 12.1 5.1‡ 7.3
5.0 6.6 7.6 2.4 2.8
4.4 3.0† 4.5 2.7‡ 4.4
2.9 1.6 1.4 0.4 0.6
1.9 2.3§ 1.6 1.2 0.8
1.2 1.2 0.9 0.3 0.2
3.6 2.3§ 1.6 1.6 1.2
0.6 10.7† 13.0 5.7‡ 7.9
roup and renal function group. †p  0.01 for comparison of ENOX versus UFH. ‡p  0.001 for
NOX vs. UFH), Adjusted for Baseline Risk
io [95% CI] ENOX vs. UFH), Adjusted for Baseline Risk
CrCl (ml/min)
30–60 >60–90 >90
0.94 (0.78–1.12) 0.78 (0.66–0.92) 0.69 (0.56–0.84)
0.97 (0.79–1.19) 0.87 (0.71–1.06) 0.92 (0.67–1.28)
0.88 (0.63–1.23) 0.68 (0.53–0.88) 0.58 (0.45–0.76)
0.68 (0.43–1.08) 1.43 (0.93–2.21) 0.77 (0.38–1.54)
1.73 (1.11–2.70) 1.91 (1.30–2.82) 1.49 (0.89–2.48)
0.73 (0.37–1.42) 1.66 (0.99–2.81) 3.33 (0.92–12.13)
1.46 (1.04–2.04) 1.51 (1.06–2.15) 1.37 (0.91–2.06)
0.98 (0.83–1.17) 0.83 (0.71–0.97) 0.71 (0.58–0.86)0
U
(n 
1
1
2
ation gCI] E
Ratlt calculation of CrCl). *Net clinical benefit.
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Renal Dysfunction and the ExTRACT-TIMI 25 Trial June 12, 2007:2249–55ntracranial bleeding, irrespective of assigned antithrom-
otic strategy. Although, by trial design, the dose of ENOX
as halved in those with CrCl 30 ml/min (1.0 mg/kg
very 24 h), excess bleeding was still observed with ENOX
n this group. This observation, albeit limited by the small
umber of subjects, suggests that until alternative dosing
egimens are developed, ENOX should not be administered
o patients with a known CrCl 30 ml/min.
For patients with well preserved renal function (CrCl
90 ml/min) major bleeding did not differ significantly
etween ENOX and UFH, although a numerically higher
leeding rate was seen with ENOX. However, with renal
ysfunction, bleeding with ENOX was significantly higher
han with UFH. This raises the possibility that dose
djustment of ENOX might be required in patients with
ven moderate renal dysfunction (e.g., CrCl 30 to 90
l/min) (23,27) to achieve the benefits of administration of
NOX throughout the index hospital stay while minimiz-
ng the risk of bleeding. This is beyond the steps taken in
his trial to reduce the dose of ENOX in those with
stimated CrCl30 ml/min as well as in patients75 years
f age.
onclusions
enal dysfunction is an important independent predictor of
dverse outcome—death, stroke, and bleeding—in STEMI
atients receiving fibrinolytic therapy. The net clinical
enefit (the composite of death, nonfatal MI, or nonfatal
ajor bleeding) was significantly superior for ENOX for a
arge majority of the study population (the 79% of the trial
opulation with CrCl 60 ml/min). With more severe
egrees of renal dysfunction, net clinical benefit did not
Figure 2 Death or Nonfatal Recurrent MI at 30 Days in
Strata of CrCl According to Treatment Assignment
CrCl  creatinine clearance; ENOX  enoxaparin; MI  myocardial infarction;
ORadj  odds ratio adjusted for baseline risk; UFH  unfractionated heparin.iffer between patients treated with ENOX and UFH.eprint requests and correspondence: Dr. Elliott M. Antman,
IMI Study Group, 350 Longwood Avenue, First Floor, Boston,
assachusetts 02115. E-mail: eantman@rics.bwh.harvard.edu.
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